Source: European Medicines Agency (EU) Revision Year: 2021 Publisher: Eckert & Ziegler Radiopharma GmbH, Robert-Rössle-Str. 10, D-13125 Berlin, Germany
Pharmacotherapeutic group: Other therapeutic radiopharmaceuticals
ATC code: V10X
The pharmacodynamic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled. Refer to the Summary of Product Characteristics/package leaflet of the particular medicinal product to be radiolabelled.
The pharmacokinetic properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga, prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
In the rat, following intravenous administration, Yttrium (90Y) chloride is rapidly cleared from the blood. At 1 and 24 hours, blood radioactivity decreases from 11.0% to 0.14% of the administered activity. The two main organs where Yttrium (90Y) chloride distributes are the liver and bones. In the liver, 18% of the injected activity is taken up 5 min after injection. Liver uptake decreases then to 8.4% 24 hours after injection. In bone, percentage of injected activity increases from 3.1% at 5 min to 18% at 6 hours and then decreases with time. Faecal and urinary elimination is slow: about 31 % of the administered activity is eliminated in 15 days.
The toxicological properties of Yttrium (90Y)-labelled medicinal products prepared by radiolabelling with Yttriga prior to administration, will be dependent on the nature of the medicinal product to be radiolabelled.
There are no data available on the toxicity of Yttrium (90Y) chloride nor on its effects on reproduction in animals or its mutagenic or carcinogenic potential.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
